HARMONY BIOSCIENCES TO PARTICIPATE IN OPPENHEIMER MOVERS IN RARE DISEASE SUMMIT
Harmony Biosciences (Nasdaq: HRMY) has announced its participation in the Oppenheimer Movers in Rare Disease Summit in New York.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Harmony Biosciences (Nasdaq: HRMY) has announced its participation in the Oppenheimer Movers in Rare Disease Summit in New York. The company's management team will engage in a fireside chat scheduled for Thursday, December 12, 2024, at 9:00 a.m. ET. Interested parties can access a webcast of the discussion through the investor relations section of Harmony's website.
Details
News Market Reaction – HRMY
The recorded move for HRMY in the trading session of this news was -1.79%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
A webcast of the fireside chat will be available on the investor page of Harmony's website at https://ir.harmonybiosciences.com/.
About Harmony Biosciences
Harmony Biosciences is a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases who have unmet medical needs. Driven by novel science, visionary thinking, and a commitment to those who feel overlooked, Harmony Biosciences is nurturing a future full of therapeutic possibilities that may enable patients with rare neurological diseases to truly thrive. Established by Paragon Biosciences, LLC, in 2017 and headquartered in Plymouth Meeting, Pa, we believe that when empathy and innovation meet, a better future can begin; a vision evident in the therapeutic innovations we advance, the culture we cultivate, and the community programs we foster. For more information, please visit www.harmonybiosciences.com.
Harmony Biosciences Investor Contact:
Brennan Doyle
484-539-9700
bdoyle@harmonybiosciences.com
Harmony Biosciences Media Contact:
Cate McCanless
202-641-6086
cmccanless@harmonybiosciences.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/harmony-biosciences-to-participate-in-oppenheimer-movers-in-rare-disease-summit-302320185.html
SOURCE Harmony Biosciences
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.